Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis

Leiper, Keith, Martin, Kate, Ellis, Anthony, Subramanian, Sreedhar, Watson, Alastair J ORCID: https://orcid.org/0000-0003-3326-0426, Christmas, Steve E, Howarth, Deborah, Campbell, Fiona and Rhodes, Jonathan M (2011) Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut, 60 (11). pp. 1520-1526. ISSN 0017-5749

Full text not available from this repository.

Abstract

To assess the safety and efficacy of the B lymphocyte (anti-CD20) antibody, rituximab, in the treatment of steroid-resistant moderately active ulcerative colitis (UC).

Item Type:	Article
Uncontrolled Keywords:	adult,antibodies, monoclonal, murine-derived,antigens, cd19,antigens, cd20,b-lymphocytes,colitis, ulcerative,colon,female,glucocorticoids,humans,immunohistochemistry,immunosuppressive agents,lymphocyte count,middle aged,remission induction
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Gastroenterology and Gut Biology
Depositing User:	Pure Connector
Date Deposited:	07 Jul 2014 13:44
Last Modified:	21 Aug 2023 00:25
URI:	https://ueaeprints.uea.ac.uk/id/eprint/48953
DOI:	10.1136/gut.2010.225482

Actions (login required)

View Item